1. Home
  2. NWS vs BIIB Comparison

NWS vs BIIB Comparison

Compare NWS & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo News Corporation Class B

NWS

News Corporation Class B

HOLD

Current Price

$29.68

Market Cap

16.2B

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$181.61

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NWS
BIIB
Founded
2012
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Newspapers/Magazines
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.2B
24.2B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
NWS
BIIB
Price
$29.68
$181.61
Analyst Decision
Strong Buy
Buy
Analyst Count
7
23
Target Price
$37.95
$176.48
AVG Volume (30 Days)
754.5K
1.9M
Earning Date
11-06-2025
10-30-2025
Dividend Yield
0.68%
N/A
EPS Growth
230.83
N/A
EPS
2.06
10.97
Revenue
$8,500,000,000.00
$10,065,900,000.00
Revenue This Year
$5.10
$3.61
Revenue Next Year
$3.24
N/A
P/E Ratio
$12.98
$16.52
Revenue Growth
2.20
4.77
52 Week Low
$26.25
$110.04
52 Week High
$35.58
$185.17

Technical Indicators

Market Signals
Indicator
NWS
BIIB
Relative Strength Index (RSI) 51.01 72.92
Support Level $28.69 $174.53
Resistance Level $29.59 $182.94
Average True Range (ATR) 0.55 5.22
MACD 0.12 0.25
Stochastic Oscillator 89.67 83.54

Price Performance

Historical Comparison
NWS
BIIB

About NWS News Corporation Class B

News Corporation is a diversified media conglomerate with large presence in the US, the UK, and Australia. Key mastheads include The Wall Street Journal, Barron's, New York Post, The Times, The Sun, The Australian, Herald Sun, and The Daily Telegraph. Its 61%-owned REA Group is the dominant property listings platform in Australia. In addition, it owns Harper Collins, one of the largest book publishers in the world, and has a sizable US digital property advertising business, Move. The 65% interest in Foxtel, the Australian pay-TV and streaming provider, was sold in April 2025. The sale to global sports streaming platform, DAZN, was struck at more than 7 times Foxtel's EBITDA.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: